Penile Fibrosis

Penile fibrosis is not a single disease. It is a general term that describes abnormal scar-like remodeling of one or several penile tissues. Depending on the tissue involved, the same underlying process — excess deposition of extracellular matrix and altered tissue mechanics — can produce very different clinical pictures.

This dossier is written for readers who want a clear, evidence-based overview of what penile fibrosis is, why it develops, how it is diagnosed and how it can be managed. It complements the AARO LAB dossiers on Peyronie's disease, fibrosis and the extracellular matrix.

• Penile fibrosis is a broad term that refers to abnormal scar-like remodeling of one or several penile tissues, not a single disease.
• It may affect the tunica albuginea, the corpora cavernosa or, less commonly, superficial penile structures.
• Peyronie's disease is one specific form of localized fibrosis of the tunica albuginea; not every penile fibrosis is Peyronie's disease.
• Corporal or cavernosal fibrosis can impair the ability of erectile tissue to expand, and may contribute to erectile dysfunction.
• Causes and prognosis vary widely — from trauma and priapism to intracavernosal injections, penile surgery, radiation, diabetes and chronic vascular dysfunction.
• Early clinical evaluation by a urologist helps identify the underlying process and orient management.
• Treatment depends on anatomy, severity, stage and cause; no single approach fits every situation.

Penile fibrosis is the abnormal accumulation and remodeling of scar-like extracellular matrix within penile tissues. It can affect the tunica albuginea, the corpora cavernosa or, less commonly, superficial structures, reducing elasticity and sometimes altering shape or erectile function.

Biologically, it reflects a fibrotic response — the same core process that drives fibrosis in other organs such as the lung, liver, kidney or skin — but applied to specialized penile tissues with unique mechanical demands. The consequences depend on which tissue is affected, how extensive the remodeling is, and how much cavernosal smooth muscle is preserved.

Understanding penile fibrosis requires a basic view of the tissues involved. The penis is a compartmentalized organ where fibrous, erectile, muscular and vascular structures work together during erection.

Table 1 — Penile tissues and possible fibrotic changes.

Penile fibrosis is commonly described by the tissue involved and by the pattern of the lesion — localized (typically a plaque) or diffuse (involving a larger volume of tissue).

Table 2 — Localized versus diffuse penile fibrosis.

Peyronie's disease is one specific form of localized fibrosis of the tunica albuginea. Not every penile fibrosis is Peyronie's disease, and the two terms should not be used interchangeably.

Table 3 — Penile fibrosis versus Peyronie's disease.

For a complete review of Peyronie's disease — including plaque formation, staging and treatment — see the dedicated dossier on Peyronie's disease. Both conditions can coexist in the same patient.

Deep penile fibrosis is distinct from superficial scarring of the penile skin. Skin scars after injury, minor surgery or infections belong to a dermatological rather than an andrological evaluation, even though they may be described in general terms as "scar tissue on the penis".

Superficial skin lesions, foreskin conditions and localized dermatological problems are not covered by this page and should be assessed on their own clinical merits.

Corporal fibrosis refers to fibrotic remodeling of the corpora cavernosa. It typically involves excess collagen deposition and loss of cavernosal smooth muscle, which reduces the ability of these tissues to expand during erection. The related term "cavernosal fibrosis" is often used with a similar meaning.

Corporal fibrosis is not automatically synonymous with Peyronie's disease. It can be:

• Focal, at sites of trauma, prior injection or surgery.
• Diffuse, when it affects a large volume of erectile tissue.
• Post-ischemic, particularly after prolonged priapism.
• Post-surgical, notably after radical pelvic surgery or prosthesis revision.

Extensive corporal fibrosis can complicate cavernosal dilation during surgery, alter the choice of prosthetic device and increase the technical complexity of implantation.

Penile fibrosis has multiple potential causes, ranging from localized mechanical injury to systemic vascular and metabolic disease. In many patients, several factors coexist.

Table 4 — Main causes, proposed mechanisms and typical tissues involved.

Symptoms depend on the tissue affected, the extent and stage of the fibrosis, and the presence or absence of an underlying condition such as Peyronie's disease. Some patients are asymptomatic; others present with clear structural or functional changes.

• Palpable plaque or firm nodular area.
• Penile curvature during erection.
• Indentation or hourglass deformity of the shaft.
• Loss of penile length (shortening).
• Reduced girth or asymmetric filling.
• Loss of elasticity or reduced expansion during erection.
• Pain, especially with erection (typically in active Peyronie's disease).
• Erectile dysfunction, particularly when cavernosal tissue is involved.
• Difficulty with penetration due to shape change or reduced rigidity.

Symptoms are typically evaluated together — a palpable plaque with new curvature and pain during erection strongly suggests active Peyronie's disease, whereas progressive erectile dysfunction with reduced expansion may indicate a cavernosal process.

Internal penile fibrosis is not always visible from the outside. Some forms cause a visible curvature, indentation or hourglass deformity during erection. A palpable plaque may be present without any visible skin change. Superficial skin scars are distinct from deep penile fibrosis.

Photographs alone cannot establish a diagnosis. The same visible shape change can correspond to different underlying processes, and important cavernosal changes may be invisible externally. Clinical evaluation and imaging remain essential. This page uses anatomical medical illustrations rather than explicit photographs.

Regardless of the trigger, penile fibrosis typically follows a similar biological sequence, driven by fibroblast activation, TGF-β signaling and altered matrix turnover.

1. 1. Tissue injury

   Mechanical trauma, hypoxia, ischemia, radiation or surgical incision damages penile tissue and triggers a repair program.

2. 2. Inflammatory signaling

   Injured cells release cytokines and pro-inflammatory mediators, recruiting immune cells to the site.

3. 3. Fibroblast activation

   Resident fibroblasts proliferate and become activated in response to TGF-β and mechanical cues.

4. 4. Myofibroblast differentiation

   Activated fibroblasts differentiate into contractile myofibroblasts (α-SMA positive), a hallmark of tissue fibrosis.

5. 5. Extracellular matrix accumulation

   Myofibroblasts deposit large amounts of type I and III collagen and other matrix components in penile tissue.

6. 6. Matrix cross-linking and organization

   Lysyl oxidase (LOX) cross-links collagen fibers; the matrix becomes stiffer and more disorganized.

7. 7. Reduced degradation

   The balance between matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) shifts toward preservation of the fibrotic matrix.

8. 8. Smooth muscle loss

   Cavernosal smooth muscle cells undergo apoptosis or are progressively replaced by collagen, reducing erectile compliance.

9. 9. Tissue stiffening and hypoxia

   The stiff fibrotic matrix and reduced perfusion further reinforce myofibroblast activation and oxidative stress, sustaining the fibrotic loop.

For a general overview of these mechanisms across organs, see fibrosis and extracellular matrix.

Diagnosis is based on medical history, physical examination and, most often, penile ultrasound. Doppler assessment, induced erection or MRI may be added in selected cases. A clinical diagnosis cannot be made from an online image.

Table 5 — Diagnostic methods for penile fibrosis.

Reversibility varies. Some early cellular changes may be partially modifiable, especially when the underlying cause is addressed. Mature, cross-linked fibrosis is generally difficult to reverse. Reversibility depends on cause, tissue, stage, extent and response to treatment.

"Improvement" does not necessarily mean a return to normal tissue. In many cases, the realistic goal of treatment is to stabilize the process, limit progression and preserve function rather than to fully undo established fibrosis.

Table 6 — Early versus established fibrosis.

Factors influencing reversibility.

• Stage — early, cellular changes may be more modifiable than mature, cross-linked fibrosis.
• Cause — treating the underlying trigger (e.g. avoiding repeated priapism episodes) may limit progression.
• Localization — focal albugineal fibrosis differs from diffuse cavernosal involvement.
• Severity — extensive smooth muscle loss is difficult to reverse.
• Vascular status — preserved cavernosal blood flow supports better tissue outcomes.
• Smooth muscle preservation — the more smooth muscle remains, the better the functional potential.
• Duration — longer-standing fibrosis is generally less reversible.
• Response to treatment — individual variability plays a major role.

Treatment of penile fibrosis depends on the type, cause and stage of the process. It combines management of the underlying condition, targeted therapies and, when needed, surgery. There is no single approach that fits every situation.

Table 7 — Main treatment approaches and their typical role.

Severe corporal fibrosis may complicate the placement of a penile prosthesis. It can make cavernosal dilation more difficult, influence the choice of device, and increase the technical demands of surgery.

Decisions about prosthetic surgery in this context are individualized and belong to specialized urological consultation. This dossier does not recommend or compare specific prosthetic brands or models.

At present, no dietary supplement is validated as a treatment for penile fibrosis. Available data are largely preclinical or exploratory. Theoretical antioxidant or anti-inflammatory effects do not demonstrate a clinical antifibrotic benefit.

Preliminary studies have explored compounds such as antioxidants, polyphenols and other nutritional factors in preclinical fibrosis models. These results should not be extrapolated to a proven clinical effect in humans. Statements suggesting that a supplement "reverses", "cures" or "treats" penile fibrosis are not supported by current evidence.

Research on penile fibrosis is organized around three levels: validated clinical care, emerging therapeutic strategies and experimental biological targets.

• Established clinical approaches

  Guideline-based management of Peyronie's disease, surgical care of deforming plaques, penile prosthesis in refractory erectile dysfunction, and treatment of underlying causes such as priapism and cardiovascular risk factors.

• Emerging therapeutic strategies

  Studies exploring antifibrotic modulation, TGF-β pathway targeting, PDE5 inhibitor use in tissue rehabilitation, and structured post-surgical protocols aimed at preserving cavernosal tissue.

• Experimental biological targets

  Preclinical research on stem cells, tissue engineering, extracellular matrix modulation, nitric oxide signaling, oxidative stress mitigation and smooth muscle preservation. Most of these remain experimental.

Most emerging and experimental strategies remain investigational and should not be presented as validated clinical treatments.

A urologist should be consulted for any persistent penile lump, new curvature, indentation, shortening, pain during erection or new erectile dysfunction. Early evaluation helps identify the underlying process and orient management before fibrotic remodeling becomes established.

Symptoms such as prolonged erection (lasting more than four hours), acute penile trauma or sudden penile pain require urgent medical attention.

A selection of reference publications used to write this dossier. Titles are kept in their original English wording.